Authors/Disclosures
|
Gene L. Bowman, ND
(Harvard Medical School, Massachusetts General Brigham)
|
No disclosure on file |
|
Hiroko H. Dodge, PhD
(Massachusetts General Hospital)
|
No disclosure on file |
|
Lisa Silbert, MD, FAAN
(OHSU)
|
The institution of Dr. Silbert has received research support from the NIH. Dr. Silbert has received personal compensation in the range of $0-$499 for serving as a Peer Reviewer, study section with NIH. |
|
David N. Herrmann, MD, FAAN
(University of Rochester Medical Center)
|
Dr. Herrmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acceleron. Dr. Herrmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint global. Dr. Herrmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Herrmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Herrmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Herrmann has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Herrmann has received intellectual property interests from a discovery or technology relating to health care. |
|
Lynne Shinto, ND
(Oregon Health and Science University)
|
No disclosure on file |
|
Jeffrey A. Kaye, MD, FAAN
(Oregon Hlth Sci Univ.)
|
Dr. Kaye has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Kaye has stock in Life Analytics. The institution of Dr. Kaye has received research support from NIH. The institution of Dr. Kaye has received research support from NSF. The institution of Dr. Kaye has received research support from AbbVie. Dr. Kaye has received intellectual property interests from a discovery or technology relating to health care. |
|
Joseph F. Quinn, MD, FAAN
(OHSU Neurology)
|
Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities. |